All Sites This Site

Find a Program

Find a Lab

MESSAGE FROM THE CHIEF


Scot H. Merrick, M.D.

Professor & Chief,
Division of Adult Cardiothoracic Surgery

 

Read message »

Make a Gift

A gift to the Dept of Surgery
helps us discover new
treatments and cures.

 

Read more »

Adult Cardiothoracic »  News & Events

Select by Date:

The Problem of Funding in Surgical Research

Scientists and Engineers for America (SEA) - May 20, 2008
Mark Ratcliffe, M.D."Surgeons may be capable of accelerating the translation of basic research into new clinical therapies. Nevertheless, most surgeon-scientists believe they are at a disadvantage in competing for peer-reviewed funding, despite a recent emphasis on "translational science" by organizations such as the NIH."

UCSF Marks Milestone with 500th Transplant in Heart and Lung Transplant

UCSF News, CA - Apr 24, 2008

"We're glad to reach this significant point in our program because it means that a great number of patients are receiving improvements to their health that could not otherwise be achieved without an organ transplant," said Charles Hoopes, MD, director of Cardiopulmonary Transplantation at UCSF since 2002. "UCSF has a highly experienced transplant support team and is dedicated to research focused on continued improvement in patient survival and outcomes for transplanted organs."

Annual Thoracic Oncology Program Retreat on April 17, 2008

Thoracic Oncology Program - Apr 09, 2008

The annual UCSF Thoracic Oncology Program Retreat will be held this Thursday, April 17th from 8:00 to 2:00 p.m.

Dr. Passi Janne, MD, Ph.D., Dana-Farber Cancer Institute will be our guest speaker this year. Dr. Janne's main research interests include the study of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) and their impact on EGFR-targeted therapeutic agents such Erlotinib and Getfitinib. EGFR mutations occur primarily in a small segment of lung cancer patients, but these patients have a high response rates to such treatments. Dr. Janne's lab is studying mechanisms of developing resistance to these agents and to identify novel ways to overcome the resistance using newer agents in the labs and in clinical trials.

Survival rates exceed national averages for UCSF heart, liver and lung transplant programs

UCSF News - Feb 29, 2008

"One-year survival rates for patients receiving heart, liver and lung transplants at UCSF Medical Center exceed national averages at statistically significant levels, according to new data compiled by the Scientific Registry of Transplant Recipients (SRTR)."

Pierre Theodore Named Van Auken Endowed Chair in Thoracic Oncology

UCSF Today, CA - Nov 01, 2007

Dr. Pierre Theodore was named the recipient of the newly created Van Auken Endowed Chair in Thoracic Oncology. Dr.Theodore, an Assistant Professor of Surgery performs lung transplants and surgery for lung cancer, mesothelioma, esophageal cancer.

Being Small Has Its Advantages, Especially With Minimally Invasive Lung Surgery

San Francisco Chronicle - Feb 11, 2007

Dr. Jasleen Kukreja "is not the first surgeon to perform a minimally invasive lobectomy at UCSF, but she may be a pioneer in the two-finger clamp technique, because her predecessors are men who have a tougher time squeezing in both fingers. Last summer, she became the first doctor to be hired by UCSF to focus primarily on this discipline."

Beijing Conference To Address Lung Cancer Crisis In China

UCSF News - Oct 23, 2002

“We will discuss the most sophisticated approaches to lung cancer in the world,” said David Jablons, MD, UCSF associate professor of surgery and program leader of the UCSF Thoracic Oncology Program. “Both the scope of the problem and the barriers to care in China are dramatic, but we hope this conference can help rally the international scientific community to address the crisis.” Jablons, who conducts translational research into targeted cancer therapies, is director of the UCSF Thoracic Oncology Laboratory."

 Email Page  
Send Email to *: (You can include up to four email addresses, separated by a comma)
Your Email Address *:
Email Subject *:
Comment: (maximum of 200 characters)

* required fields